Health Care & Life Sciences » Biotechnology | Audentes Therapeutics Inc.

Audentes Therapeutics Inc. | Mutual Funds

Mutual Funds that own Audentes Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Puritan Fund
1,349,700
3.62%
0
0.17%
07/31/2018
T Rowe Price Health Sciences Fund
965,024
2.59%
46,706
0.28%
06/30/2018
SPDR S&P Biotech ETF
801,145
2.15%
2,061
0.5%
09/06/2018
T Rowe Price New Horizons Fund
720,453
1.93%
137,056
0.11%
06/30/2018
Fidelity Select Biotechnology Portfolio
702,014
1.88%
-22,800
0.28%
07/31/2018
Vanguard Total Stock Market Index Fund
692,899
1.86%
0
0%
07/31/2018
Prudential Jennison Health Sciences Fund
687,019
1.84%
0
0.98%
07/31/2018
iShares Russell 2000 ETF
670,210
1.8%
-357
0.05%
09/06/2018
Fidelity Series Small Cap Opportunities Fund
587,700
1.57%
-27,300
0.33%
04/30/2018
Fidelity Small Cap Growth Fund
537,121
1.44%
-3,549
0.42%
04/30/2018

About Audentes Therapeutics

View Profile
Address
600 California Street
San Francisco California 94108
United States
Employees -
Website http://www.audentestx.com
Updated 07/08/2019
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.